A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)

Trial Profile

A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Vorinostat (Primary) ; Vorinostat (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Sep 2014 Status changed from suspended to active, no longer recruiting as reported by the ClinicalTrials.gov record.
    • 15 Jan 2014 Status changed from recruiting to suspended as reported by the ClinicalTrials.gov record.
    • 03 Aug 2012 Planned End Date changed from 1 Sep 2010 to 1 Nov 2020 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top